Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Lipid levels in the blood are proposed to play a role in the progression of diabetic retinopathy. Lipid levels can be controlled with dyslipidemic drugs, such as fenofibrate. Fenofibrate is known to prevent diabetic microvascular complications by decreasing cholesterol and triglyceride levels. This study aims to investigate the effects of oral fenofibrate on central macular thickness (CMT) and macular volume, as well as on specific biomarkers of endothelial dysfunction (eNOS), inflammation (VCAM-1), and angiogenesis (VEGF) in DR individuals with dyslipidemia.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• Adults with type 2 DM

• Confirmed DR (with bio-microscopy examination and fundus photos of both eyes)

• Dyslipidemia or normal lipid profile with treatment

• Sign informed consent

Exclusion Criteria:

• Subjects with severe renal failure

• Subjects with allergy towards fenofibrate

• Pregnant women

• Subjects who have undergone laser photocoagulation treatment or intravitreal injection in last 6 months